Tenofovir Disoproxil Isopropoxycarbonyl

Tenofovir Disoproxil Isopropoxycarbonyl (TDI) is a prodrug of Tenofovir Disoproxil Fumarate (TDF), which is a nucleotide reverse transcriptase inhibitor used for the treatment of HIV and chronic Hepatitis B virus infections. TDI is a water-soluble ester that is rapidly metabolized in vivo to TDF. The prodrug form was developed to improve the bioavailability of TDF, which has low oral bioavailability due to its hydrophilic nature and high molecular weight. TDI is administered orally in the form of tablets or capsules. It is rapidly hydrolyzed in the gastrointestinal tract to release TDF, which is then absorbed into the bloodstream. Once in the bloodstream, TDF is converted into its active form, tenofovir diphosphate, which inhibits the ability of the virus to replicate. The chemical structure of TDI is similar to that of TDF, with the addition of an isopropoxycarbonyl group. This group enhances the lipophilicity of the molecule, allowing for better absorption and distribution in the body. TDI has been shown to be effective in reducing HIV viral load and improving immune function in clinical trials. It is generally well-tolerated, with side effects including diarrhea, nausea, and headache reported in some patients. In conclusion, Tenofovir Disoproxil Isopropoxycarbonyl is a prodrug of Tenofovir Disoproxil Fumarate that is used for the treatment of HIV and chronic Hepatitis B virus infections. Its chemical structure enhances the bioavailability and lipophilicity of the molecule, allowing for better absorption and distribution in the body. It is generally well-tolerated, with side effects reported in some patients.